Abstract: Perioperative immunotherapy for non-small cell lung cancer (NSCLC) has attracted increasing attention of researchers in recent years. The success of phase Ⅲ clinical studies of neoadjuvant and adjuvant therapies for NSCLC has demonstrated the value of immunotherapy. Numerous studies on perioperative NSCLC immunotherapy were reported and updated in 2022. These studies attempted to answer some critical issues, such as the possible survival benefits of immunotherapy, identification of the population it benefits, and reliability of surrogate endpoints. The results of these studies have triggered new perspectives on this therapeutic approach. In this article, we review the progress in research on perioperative immunotherapy for NSCLC in 2022.